Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of RSV and Influenza Combination Vaccines in Older Adults
NCT05788237Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2023
- Primary completion
- Sep 2023
- Modality
- Vaccine mRNA, mRNA Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07941314 in respiratory syncytial virus infection (RSV) and influenza (4 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants With Local Reactions Within 7 Days After Vaccination, Percentage of Participants With Systemic Events Within 7 Days After Vaccination and 4 more. Started Mar 2023; status: completed.
02
Drugs
PF-07941314
03
Conditions
respiratory syncytial virus infection (RSV)influenza
Beyond the preview
Go deeper on NCT05788237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05788237.